Sarepta Therapeutics buy tamam
Start price
09.01.18
/
50%
€48.59
Target price
04.11.21
€153.34
Performance (%)
57.44%
End price
05.11.21
€76.50
Summary
This prediction ended on 05.11.21 with a price of €76.50. With a performance of 57.44% the BUY prediction by tamam was a big success. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Sarepta Therapeutics | 1.039% | 1.039% | -56.541% | -88.692% |
| iShares Core DAX® | 1,11 % | 3,98 % | 5,62 % | 49,88 % |
| iShares Nasdaq 100 | 3,27 % | 5,22 % | 41,16 % | 91,99 % |
| iShares Nikkei 225® | 5,78 % | 11,58 % | 64,35 % | 72,79 % |
| iShares S&P 500 | 1,64 % | 2,44 % | 27,36 % | 66,76 % |
Comments by tamam for this prediction
In the thread Sarepta Therapeutics diskutieren
Sarepta continues to be a core buy in biotech
In today´s investor update management guided for fourth quarter revenue of $57.3 million and full year 2018 Exondys 51 revenue in the range of $295 million to $305 million (roughly double that of 2017).
tamam stimmt am 09.01.2018 der Outperform-Einschätzung der institutionellen Analysten zu.
In the thread Trading Sarepta Therapeutics
Die von tamam gewählte maximale Laufzeit wurde überschritten